Clinical characteristics and efficiency of balloon dilation (II)
| Study | Balloon types | Control | Definition of success rate | Reported success rate (%) | Follow-up |
| Virasoro et al28 | Optilume drug-coated balloon (DCB) | / | Functional success was defined as ≥50% reduction in International Prostate Symptom Score without need for retreatment. | 67 | 3 years |
| Elliott et al27 | Optilume DCB | dilation/DVIU | Anatomical success: the proportion of participants in whom the surgeons could atraumatically pass a 16-French flexible cystoscope or a 14-French catheter through the treated area at 6 months | 74.6:26.8 | 1 year |
| Beeder et al32 | 8 cm, 24-French UroMax Ultra balloon dilator | / | Proportion of patients who reported no recurrence of lower urinary tract symptoms or did not need further stricture treatment | 50 | 12 months (3–40) |
| Alibekov et al33 | / | / | Proportion of patients without recurrence of urethral stricture 18 months of dilation | 85.7 | 14 months (3–24) |
| Yi et al34 | 8 cm, 24-French UroMax Ultra balloon dilator | / | Proportion of patients with no postoperative recurrence of urethral stricture or who did not need further stricture treatment | 66.3 | 8.4 months (IQR, 3.9–22) |
| Kumano et al30 | Balloon dilation catheter (X-FORCE; BARD Medical, Murray Hill, New Jersey, USA) | OIU | Proportion of patients with no recurrence of stricture during the follow-up period | 84:22 | / |
| Zhou et al35 | Balloon catheter (X-Force, C.R. Bard, USA) | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 86.7 | 6–24 months |
| Yu et al31 | 6 cm, 7-French balloon catheter (X-Force, C.R. Bard, USA) | DVIU | Proportion of patients with no postoperative recurrent urethral stricture or who did not need further stricture treatment | 35.5 | 14.75 months (5–36) |
| Chhabra et al36 | 8 cm, 24-French urethral Balloon catheter set (Cook Urological, Spencer, Indiana, USA) | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 84.4 | 24 months (3–52) |
| Ishii et al37 | 6 cm, 6-French Balloon catheter, the X Force | / | Proportion of patients with no recurrence of strictureduring the follow-up period | 80 | 24 months (7–67) |
| Mao et al38 | 24-French Nephrostomy balloon dilation catheter, the X Force | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 64.9 | / |
| Vyas et al39 | 8 cm, 24-French urethral Balloon catheter set (Cook Urological, Spencer) | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 68 | 6 months (2–60) |
| Alguersuari et al40 | Fluoroscopic-guided balloon dilation | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 69 | / |
| MacDiarmid et al41 | The UrethraMax (4, 6 or 8 cm; 24-French) or a coude tip balloon dilation catheter | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 55 | 9 months (1–16) |
| Mohammed and Wirima29 | Olbert balloon catheter | / | Proportion of patients who did not need further stricture treatment during the follow-up period | 66.7 | 12 months (6–26) |
DVIU, direct vision internal urethrotomy; OIU, optical internal urethrotomy.